848. Menstrual Cycle, ADHD, and PMDD in Women: Neurobiological Mechanisms and Clinical Implications

Abstract

Abstract Background Women with ADHD are at elevated risk for premenstrual dysphoric disorder (PMDD) and depression due to increased biological sensitivity to hormonal fluctuations that influence neurotransmitter systems. Estrogen and progesterone modulate dopaminergic pathways, which are integral to cognitive and emotional regulation. Thus, cyclical hormonal changes inherent to the menstrual cycle significantly affect the severity of ADHD symptoms in women. Aims & Objectives This study explores how hormonal fluctuations during the menstrual cycle affect ADHD symptoms in women. The objectives are to examine neurobiological mechanisms underlying symptom changes, clarify PMDD pathophysiology, assess current management approaches, and highlight priorities for future research. Method A narrative review of English-language literature in PubMed and EMBASE was conducted up to February 2025. Results PMDD arises from complex neurobiological, hormonal, and genetic interactions, resulting in altered brain sensitivity to hormonal fluctuations during the luteal phase. Key factors include allopregnanolone (a progesterone metabolite affecting GABA receptors) and estradiol, which together influence neurotransmission. PMDD is also linked to decreased serotonin and abnormal biological rhythms, such as lower melatonin and disrupted sleep. Immune changes and elevated inflammation (e.g., higher CRP) may exacerbate symptoms. PMDD frequently co-occurs with mood disorders and is associated with greater sensitivity to stress, childhood trauma, and psychiatric comorbidities. PMDD is distinguished by a "symptom-free window" following menstruation, while Premenstrual Exacerbation (PME) involves persistent ADHD symptoms throughout the cycle, with premenstrual intensification. Accurate differentiation requires tracking symptoms prospectively for at least two cycles and using instruments like the Daily Record of Severity of Problems (DRSP). PMDD causes clinically significant distress or impairment in functioning. Women with both ADHD and PMDD often lose behavioral control during the luteal phase, exhibiting increased conflict, impulsivity, and maladaptive coping (e.g., binge eating). Impulsivity peaks at ovulation (high estrogen) and premenstrually (low estrogen and impaired affective regulation). Estrogen acts as a dopamine agonist, supporting mood and cognition; its withdrawal in the luteal phase worsens ADHD symptoms. PMDD is not linked to abnormal hormone levels, but to increased sensitivity to normal fluctuations. Women with ADHD are especially vulnerable, with a sixfold higher risk of PMDD, earlier and longer depressive episodes, and increased susceptibility at puberty, postpartum, and menopause. Emotional dysregulation and perceived social inadequacy may contribute to trauma and depression. Many women with ADHD notice reduced efficacy of stimulant medication premenstrually, increasing vulnerability to symptom exacerbation and mood disturbance. Temporary dose adjustments may be considered for refractory symptoms. Hormonal contraceptives may reduce PMDD symptoms but, in young women with ADHD, are associated with a higher depression risk. Estrogen supplementation may help preserve cognitive function premenstrually. Stabilizing hormones may support consistent ADHD medication effects. Long-acting reversible contraceptives (LARCs) are associated with lower depression risk than oral contraceptives in women with ADHD. Discussion & Conclusions Women with ADHD frequently experience exacerbation of cognitive and mood symptoms in the luteal phase, driven by hormonal influences on neurotransmitter regulation and medication efficacy. Personalized treatment strategies that account for menstrual cycle phase and hormonal status may optimize management. Further research is warranted to inform evidence-based clinical recommendations.